BACTERIA-ENGINEERED TO ELICIT ANTIGEN-SPECIFIC T CELLS

Provided are modified microorganisms, such as live recombinant commensal bacteria, that express a non-native antigen, or are surface-labeled with a non-native antigen, and methods of using the modified microorganisms to induce an antigen-specific immune response to the non-native antigen. The modified microorganism can be used to induce a regulatory T cell immune response to the heterologous antigen to treat an autoimmune disease in a subject in need thereof, or can be used to induce an effector T cell immune response to the heterologous antigen to treat an infectious disease or proliferative disease in a subject in need thereof..

Medienart:

Patent

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Europäisches Patentamt - (2023) vom: 09. Aug. Zur Gesamtaufnahme - year:2023

Sprache:

Englisch

Beteiligte Personen:

FISCHBACH MICHAEL A [VerfasserIn]
NAGASHIMA KAZUKI [VerfasserIn]
CHEN YIYIN E [VerfasserIn]
BOUSBAINE DJENET [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
bio
C12N: Microorganisms or enzymes; compositions thereof; pr (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2023-08-09, Last update posted on www.tib.eu: 2024-02-06, Last updated: 2024-02-09

Patentnummer:

EP4221730

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA017853958